Shionogi & Co

Shionogi & Co Net Margin

The Net Profit Margin of Shionogi & Co (4507.T) as of Oct 15, 2026 is 41.06 %. In the previous year, Net Profit Margin was 38.89 % — a change of 5.58% (higher).

Net Margin

41.06 %

YoY

5.58%

Last updated:

Net Profit Margin of Shionogi & Co is 2026 41.06 % . Net Profit Margin of Shionogi & Co was 2025 38.89 % . It decreases by 5.58% higher compared to the previous year.

For Shionogi & Co, the net margin of 41.1% is up versus 34.1% a few years ago.

The Shionogi & Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
36.50 JPY
Jan 1, 2020
36.65 JPY
Jan 1, 2021
37.64 JPY
Jan 1, 2022
34.07 JPY
Jan 1, 2023
43.35 JPY
Jan 1, 2024
37.24 JPY
Jan 1, 2025
38.89 JPY
Jan 1, 2026
41.06 JPY
The Shionogi & Co Net Margin history
YEARNet MarginYoY
41.06 %+5.58%
38.89 %+4.42%
37.24 %-14.09%
43.35 %+27.23%
34.07 %-9.48%
37.64 %+2.69%
36.65 %+0.42%
36.50 %+15.56%
31.59 %+27.61%
24.75 %+15.05%
21.51 %+33.79%
16.08 %+11.37%
14.44 %+6,021.53%
0.24 %+132.61%
0.10 %+42.96%
0.07 %-48.86%
0.14 %+101.48%
0.07 %-41.15%
0.12 %+25.66%
0.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shionogi & Co Stock analysis

What does Shionogi & Co do? The company Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. It was founded in 1878 and has since become a significant player in the industry. It currently employs over 6,000 employees worldwide and is listed on the Tokyo Stock Exchange. Shionogi is divided into several business segments that offer different products and services. The largest segment is the pharmaceutical division, which specializes in the development and marketing of drugs. The company has strong expertise in infectious diseases, pain management, and oncology, and operates in many countries worldwide. One flagship product is the antibiotic Cefditoren, used to treat various bacterial infections. In addition to the pharmaceutical division, Shionogi is also active in other areas. For example, the company offers diagnostic and laboratory services, operating multiple labs in Japan and other countries. Another business segment is the production and marketing of nutritional supplements, sold in Japan, China, and the USA. Shionogi's business model is based on extensive research and development, as well as strong brand positioning. The company invests a significant portion of its revenue each year in the research and development of new drugs and better treatment options for existing diseases. Thanks to the high quality of its products and strong brand, the company has a loyal customer base. In recent years, Shionogi has focused on international expansion opportunities and has expanded its activities in various regions. For example, it has partnered with US pharmaceutical company Purdue Pharma to develop and market a novel pain medication. Shionogi's annual revenue is around 1.5 billion euros. The company is particularly strong in Japan and other Asian countries, but is also active in the US and Europe. In the coming years, Shionogi aims to further expand its international business and solidify its position as a significant player in the industry. Key focuses will be on the launch of new products and finding treatments for previously incurable diseases. Overall, Shionogi is an innovative and successful company that utilizes its expertise in the pharmaceutical industry in various ways. With its dedicated employees and strong brand, it will continue to play an important role in the industry. Shionogi & Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shionogi & Co stock

Net Profit Margin of Shionogi & Co is 41.06 % in 2026.

Net Profit Margin of Shionogi & Co changed from 38.89 % to 41.06 %, representing a 5.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Shionogi & Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Shionogi & Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Shionogi & Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Shionogi & Co